Published January 17, 2022 | Version v1
Other Open

Report on additional case studies (D3.8)

  • 1. Bayer AG
  • 2. UMCU

Description

The objective of Task 3.8 was to conduct prospective case studies additional to the three core case studies in PREFER. Within this task, four industry-led case studies were conducted in disease areas related to Myocardial infarction, Chronic pain, Chronic obstructive pulmonary disease and Hemophilia. Additionally, four case studies were conducted led by academia in disease areas related to Diabetes, Hemophilia, Multiple Myeloma and Rheumatoid Arthritis. These additional studies cover several decision points of different stakeholders in the medical product lifecycle. Also, they cover a large number of PREFER methodological research questions from comparison of Discrete Choice Experiments with Best-Worst-Scaling and Swing weighting as well as variations across patient groups and the assessment of educational tools. This report describes the main characteristics of the 8 additional case studies and contains summaries of all studies.

Files

115966_PREFER_Deliverable_3.8 additional case studies-final report.pdf

Additional details

Funding

European Commission
PREFER – Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 115966